CAMBRIDGE, Mass. — August 13, 2025 — Leads & Copy — Vor Bio, a clinical-stage biotechnology company, announced that its collaborator, RemeGen Co., Ltd, has achieved the primary endpoint in a Phase 3 clinical study in China evaluating telitacicept in adults with primary Sjögren’s disease. The study results are planned to be presented at an upcoming medical conference.
Telitacicept demonstrated a favorable safety profile in the study, which measured disease activity improvement by a reduction in the EULAR Sjögren’s syndrome disease activity index (ESSDAI) against placebo.
RemeGen plans to submit a Biologics License Application (BLA) to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for primary Sjögren’s disease.
Telitacicept is a novel recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL. It is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG).
Sjögren’s disease is a chronic autoimmune condition affecting moisture-producing glands and other organs, with symptoms including dry eyes and dry mouth.
Contact: Carl Mauch, cmauch@vorbio.com; Sarah Spencer, investors@vorbio.com
Source: Vor Bio
